Mitral stenosis (MS) is associated with increased thromboembolic risk, especially in individuals with atrial fibrillation (AF), a common finding in these patients.1,2 Percutaneous mitral valvuloplasty (PMV) in patients with hemodynamically significant MS is associated with a reduction in thromboembolic risk.3 Also, percutaneous left atrial appendage (LAA) closure is an emerging procedure that may be considered in patients with AF with high thromboembolic risk and in whom chronic oral anticoagulation is contraindicated.4–6

We describe the case of a patient with significant MS and a history of repeated thromboembolic events in spite of oral anticoagulation with acenocoumarol who underwent both PMV and percutaneous LAA closure in the same procedure. Synergies between the two procedures are discussed.

A 57-year-old woman with significant MS, in New York Heart Association functional class II/IV, was referred to our unit for PMV, as echocardiographic parameters were suitable (mitral area 1.1 cm2, mild mitral regurgitation, Wilkins score 7). Interestingly, she had previously undergone PMV 12 years before.

The patient had permanent AF and was treated chronically with acenocoumarol. Despite adequate oral anticoagulation, in the last four years she had presented at least two episodes of ischemic stroke: an embolic stroke two years previously in the right middle cerebral artery territory, and an embolic stroke eight months previously in the right posterior inferior cerebellar artery which caused transtentorial herniation. After these episodes the patient presented an acceptable neurological recovery and was independent for everyday activities. One month before admission, she had presented a non-ST-segment elevation acute myocardial infarction. Coronary computed tomography showed no coronary stenosis. Coronary embolism was diagnosed as the probable cause of the ischemic event and the patient had no recurrent ischemia or other complications. Our center's heart team decided to perform PMV and percutaneous LAA closure during the same procedure.

Transesophageal echocardiography performed 24 hours prior to the procedure showed no thrombus in the left appendage but revealed the presence of high-density spontaneous contrast (Figure 1). The LAA showed a 29 mm×26 mm entry orifice (Figure 2).

Figure 1.

Transesophageal echocardiographic images of the stenotic mitral valve and the thrombus-free left atrial appendage with spontaneous inner contrast.

(0.12MB).

Figure 2.

Transesophageal echocardiographic measurement of the entry orifice and length of the left atrial appendage.

(0.14MB).

In the procedure, the middle portion of the interatrial septum was punctured (Figure 3) and PMV was performed first by the usual technique with a Mullins sheath and a Brockenbrough needle and inflation of a 26 mm Inoue balloon (Figures 4 and 5), with a good result (absence of transmitral gradient, 2.1 cm2 mitral area and no increase in the degree of valvular regurgitation). Percutaneous LAA closure was then performed. Keeping the guidewire in the same transseptal puncture, a pigtail catheter was introduced into the LAA to allow selective injections into this structure (Figure 6). A 30 mm Amplatzer Cardiac Plug (ACP) (St. Jude Medical), specific for percutaneous LAA closure, was inserted via the ACP release sheath and implanted in the left appendage. It was released successfully and without complications (Figures 7 and 8).

Figure 3.

Transesophageal echocardiographic image of transseptal puncture.

(0.09MB).

Figure 4.

Transesophageal echocardiographic image of percutaneous balloon mitral valvuloplasty.

(0.14MB).

Figure 5.

Fluoroscopic image of percutaneous balloon mitral valvuloplasty.

(0.14MB).

Figure 6.

Fluoroscopic image of selective contrast injection in the left atrial appendage.

(0.25MB).

Figure 7.

Transesophageal echocardiographic three-dimensional reconstruction of inflation and release of the Amplatzer Cardiac Plug by the left atrial appendage.

(0.12MB).

Figure 8.

Fluoroscopic images of release of the Amplatzer Cardiac Plug by the left atrial appendage.

(0.21MB).

The patient was discharged on indefinite treatment with acenocoumarol, associated with aspirin (100 mg/d) for three months. After one year follow-up there have been no further embolic episodes or other complications (Figure 9).

Figure 9.

Transesophageal echocardiographic images with three-dimensional reconstruction of the Amplatzer Cardiac Plug in follow-up.

(0.1MB).

PMV is a common procedure in patients with significant MS, poor functional class and echocardiographic parameters suitable for the technique. The procedure also shows good results in patients who have previously undergone PMV, as in the case of our patient.2 What makes the case described interesting is the fact that the patient had presented numerous cardioembolic episodes in spite of adequate chronic oral anticoagulation, so it was decided to undertake a combined PMV and percutaneous LAA closure procedure to reduce the risk of post-PMV embolic recurrence. Since a number of the potential complications of percutaneous LAA closure are associated with transseptal puncture, also used for PMV, the risk of performing the two procedures together is probably lower than if they are done separately. There are technical considerations related to the site of the transseptal puncture, since the ideal position differs according to the type of procedure. In our case the puncture was performed in the mid portion of the septum, allowing a relatively easy procedure.

Significant MS increases pressure and alters flow in the left atrium. This is associated with an increased incidence of AF and hypercoagulability, both explaining the high rate of embolism in patients with this valvulopathy.3 PMV has been shown to reduce the incidence of systemic embolism in MS, and PMV is therefore recommended even in patients with significant asymptomatic MS and high thromboembolic risk.2 In the case presented, the therapeutic strategy adopted was intended not only to improve functional class, but also to reduce the risk of recurrent embolism by the double mechanism of improving hemodynamic parameters in the left atrium and excluding the LAA.

Percutaneous LAA closure is becoming increasingly common in patients with AF, high embolic risk and contraindications for anticoagulation, but very few data are available regarding this procedure in patients with rheumatic AF. The guidelines recommend LAA closure during surgical MS procedures, as it is associated with a significant reduction in risk of postoperative embolic events.7–9 Similarly, some patients undergoing PMV may also benefit from percutaneous LAA closure performed during the same operation.

Our patient was discharged under chronic oral anticoagulation, since LAA closure does not completely eliminate the risk of embolism in MS patients and she had no contraindications for this treatment. Out of 136 patients who underwent atrial appendage closure during a mitral valve operation, Almahameed et al.8 observed that thromboembolic events were more frequent in patients whose anticoagulant treatment had been stopped after 3.5 years of treatment (10% vs. 15%). The ideal anticoagulant treatment after intracavitary device implantation is unclear, suggesting the use of aspirin in our patient in the three months following the operation.

The authors have no conflicts of interest to declare.